ProShare Advisors’s ProQR Therapeutics PRQR Stock Holding History

ProShare Advisors’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-10,020	Closed	-$80K	–	2282
2021 Q4	$80K	Buy	+10,020	New	+$76.3K	﹤0.01%	2230
2020 Q1	–	Sell	-10,675	Closed	-$106K	–	1486
2019 Q4	$106K	Buy	10,675 +138	+1%	+$1.07K	﹤0.01%	1687
2019 Q3	$61K	Sell	10,537 -808	-7%	-$6.45K	﹤0.01%	1589
2019 Q2	$103K	Sell	11,345 -1,807	-14%	-$21.3K	﹤0.01%	1526
2019 Q1	$182K	Buy	13,152 +2,332	+22%	+$34.8K	﹤0.01%	1495
2018 Q4	$171K	Buy	+10,820	New	+$199K	﹤0.01%	1403

Other funds holding PRQR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

MCM

M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

ProShare Advisors's PRQR Position: Q1 2022 in Review

ProShare Advisors sold out of ProQR Therapeutics (PRQR) in Q1 2022, closing a stake of 10,020 shares — an estimated $80K sold.

ProShare Advisors first reported a position in PRQR in Q4 2018 and held it in 6 quarters. The position peaked at $182K in Q1 2019. 58 funds tracked by Wall St. Rank hold PRQR as of Q1 2022.

ProShare Advisors reported no remaining ProQR Therapeutics position as of Q1 2022 after selling out during the quarter.
ProShare Advisors sold 10,020 ProQR Therapeutics shares in Q1 2022, an estimated $80K.
ProShare Advisors first reported a position in ProQR Therapeutics in Q4 2018 and held it in 6 quarters.
ProShare Advisors's ProQR Therapeutics position peaked at $182K in Q1 2019.
58 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2022.

Based on ProShare Advisors's 13F filing for Q1 2022, filed 10 May 2022.